Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 18/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 15/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 10/20 | 0.54 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567549 | 1.00 | OPRK1 (0.57) | OPRK1KCNH2OPRM1OPRD1PARP1 | |
| SCHEMBL16618230 | 0.88 | OPRK1 (0.59) | OPRK1KCNH2OPRM1OPRD1PARP1 | |
| SCHEMBL6477823 | 0.87 | EPHX2 (0.50) | OPRK1 | |
| SCHEMBL29267960 | 0.87 | EPHX2 (0.50) | OPRK1 | |
| SCHEMBL30567543 | 0.87 | EPHX2 (0.50) | OPRK1 | |
| SCHEMBL30517690 | 0.87 | EPHX2 (0.50) | OPRK1 | |
| SCHEMBL28885485 | 0.87 | POLB (0.45) | OPRK1KCNH2OPRM1OPRD1 | |
| SCHEMBL6302570 | 0.82 | PARP10 (0.64) | OPRK1KCNH2PARP1 | |
| SCHEMBL17865584 | 0.81 | OPRK1 (0.67) | OPRK1KCNH2OPRM1OPRD1PARP1 | |
| SCHEMBL6487966 | 0.81 | PDE4D (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4651714-B2 | — | — | 2011-03-16 | — | — | JP | claimed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | claimed |
| EP-1891058-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | claimed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | claimed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | claimed |
| CN-116916914-A | SOS1 inhibitors and uses thereof | 锐新医药公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-1902052-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1891058-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | AstraZeneca AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| WO-2007007041-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2007-01-18 | — | — | WO | disclosed |
| WO-2006125972-A1 | HETEROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |